Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01188603 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics of Flibanserin in Postmenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
A Phase 1 study, sponsored by Sprout Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT01188603 is a Phase 1 study that has completed, run by Sprout Pharmaceuticals. The registered enrollment target is 24 participants.
The verdict
NCT01188603, a Phase 1 study, has completed, sponsored by Sprout Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This trial examines the way flibanserin is metabolized in postmenopausal women with Hypoactive Sexual Desire Disorder.
Interventions
- DRUG flibanserin 100 mg dose every evening
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2010-07 |
| Est. Completion | 2010-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01188603
The ClinicalTrials.gov registry entry for NCT01188603 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sprout Pharmaceuticals, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which flibanserin 100 mg dose every evening is the first listed.
NCT01188603 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01188603 about?
NCT01188603 is a clinical study titled "Pharmacokinetics of Flibanserin in Postmenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)". This trial examines the way flibanserin is metabolized in postmenopausal women with Hypoactive Sexual Desire Disorder.
What is the current status of trial NCT01188603?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2010-07. Estimated completion is 2010-10.
What interventions are being tested in trial NCT01188603?
The interventions under investigation include: flibanserin 100 mg dose every evening (DRUG).
Who is sponsoring clinical trial NCT01188603?
This trial is sponsored by Sprout Pharmaceuticals, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.